<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953979</url>
  </required_header>
  <id_info>
    <org_study_id>2008-2</org_study_id>
    <nct_id>NCT00953979</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis</brief_title>
  <official_title>A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gu Jieruo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized controlled study to evaluated the efficacy and safety of
      kunxian capsule in treating of patients with early ankylosing spondylitis (AS). The major
      outcome index is proportion of patients achieving ASAS20 response at week12, and minor
      outcome indexes include ASAS50 and ASAS70, BASDAI20,BASDAI50 and BASDAI70. The adverse events
      at any time were recorded to evaluate the safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients achieving ASAS20 response</measure>
    <time_frame>12th week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients achieving BASDAI20/50/70 response</measure>
    <time_frame>12th week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Treatment</condition>
  <arm_group>
    <arm_group_label>Sulfasalazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sulfasalazine is a drug in treatment RA, AS and ulcerative colonitis. In this study, Sulfasalazine is used to act as an active comparator to access the efficacy of kunxian capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo capsule was used to be a comparator of kunxian capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>kunxian capsule</intervention_name>
    <description>The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.</description>
    <arm_group_label>Sulfasalazine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  16 to 65 years old, having signed the informed consent;

          -  fulfill the ESSG criteria for diagnosis of SpA; not fulfill the 1984 modified NewYork
             criteria for AS;

          -  BASDAI score more than 4;

          -  stop taking DMARDs for at least 4 weeks;

          -  NSAIDs dosage has been stable for at least 4 weeks;

        Exclusion Criteria:

          -  Intra-articular injection of cortisone within 3 months.

          -  History of heart failure, multiple sclerosis, COPD, lymphoma or other tumors;

          -  Accompanied by fibromyalgia or other rheumatic diseases;

          -  Female of pregnancy or breast feeding;

          -  History of mental disease and poor compliance.

          -  History of drug abuse or alcoholism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jieruo Gu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Department, Third Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Department, the Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Gu Jieruo</investigator_full_name>
    <investigator_title>Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University</investigator_title>
  </responsible_party>
  <keyword>ankylosing spondylitis</keyword>
  <keyword>treatment</keyword>
  <keyword>Sulfasalazine</keyword>
  <keyword>kunxian capsule</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfasalazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

